98%
921
2 minutes
20
Complete tumor removal during surgery has a great impact on patient survival. To that end, the surgeon should detect the tumor, remove it and validate that there are no residual cancer cells left behind. Residual cells at the incision margin of the tissue removed during surgery are associated with tumor recurrence and poor prognosis for the patient. In order to remove the tumor tissue completely with minimal collateral damage to healthy tissue, there is a need for diagnostic tools that will differentiate between the tumor and its normal surroundings. We designed, synthesized and characterized three novel polymeric Turn-ON probes that will be activated at the tumor site by cysteine cathepsins that are highly expressed in multiple tumor types. Utilizing orthotopic breast cancer and melanoma models, which spontaneously metastasize to the brain, we studied the kinetics of our polymeric Turn-ON nano-probes. To date, numerous low molecular weight cathepsin-sensitive substrates have been reported, however, most of them suffer from rapid clearance and reduced signal shortly after administration. Here, we show an improved tumor-to-background ratio upon activation of our Turn-ON probes by cathepsins. The signal obtained from the tumor was stable and delineated the tumor boundaries during the whole surgical procedure, enabling accurate resection. Our findings show that the control groups of tumor-bearing mice, which underwent either standard surgery under white light only or under the fluorescence guidance of the commercially-available imaging agents ProSense® 680 or 5-aminolevulinic acid (5-ALA), survived for less time and suffered from tumor recurrence earlier than the group that underwent image-guided surgery (IGS) using our Turn-ON probes. Our "smart" polymeric probes can potentially assist surgeons' decision in real-time during surgery regarding the tumor margins needed to be removed, leading to improved patient outcome.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037036 | PMC |
http://dx.doi.org/10.7150/thno.23853 | DOI Listing |
Eur J Radiol
September 2025
Department of Radiology, Affiliated Hospital of Hebei University, Baoding 071000, China. Electronic address:
Purpose: The present study aimed to develop a noninvasive predictive framework that integrates clinical data, conventional radiomics, habitat imaging, and deep learning for the preoperative stratification of MGMT gene promoter methylation in glioma.
Materials And Methods: This retrospective study included 410 patients from the University of California, San Francisco, USA, and 102 patients from our hospital. Seven models were constructed using preoperative contrast-enhanced T1-weighted MRI with gadobenate dimeglumine as the contrast agent.
Pathol Res Pract
September 2025
Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China. Electronic address:
Background: Dermal clear cell sarcoma (DCCS) is a rare malignant mesenchymal neoplasm. Owing to the overlaps in its morphological and immunophenotypic profiles with a broad spectrum of tumors exhibiting melanocytic differentiation, it is frequently misdiagnosed as other tumor entities in clinical practice. By systematically analyzing the clinicopathological characteristics, immunophenotypic features, and molecular biological properties of DCCS, this study intends to further enhance pathologists' understanding of this disease and provide a valuable reference for its accurate diagnosis.
View Article and Find Full Text PDFPathol Res Pract
September 2025
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Our research aims to ascertain the value of precursor and outgrowth lepidic in aiding the confirmation of multiple lung adenocarcinomas as separate primary lung cancers (SPLC). A total of 151 patients with metachronous multiple invasive adenocarcinomas were included in this study. Driver mutation tests(at least five genes: EGFR, ALK, KRAS, BRAF, and ROS1) were conducted on 302 tumors collected from 151 patients.
View Article and Find Full Text PDFACS Appl Bio Mater
September 2025
School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
The generation of reactive oxygen species (ROS) through nanozyme-mediated sonocatalytic therapy has demonstrated remarkable therapeutic efficacy in the field of cancer. Nevertheless, it remains a significant challenge for nanozymes with a single catalytic active center to generate sufficient ROS via Fenton or Fenton-like reactions to effectively induce tumor cell death. In order to enhance the catalytic efficacy, we devised and synthesized a multiple active centre and mitochondrial-targeted perovskite nanozyme (NCFP), doped with cobalt (Co) element, and incorporated 4-carboxybutyltriphenylphosphonium bromide (TPP) as a mitochondrial targeting marker for ultrasound (US)-assisted enzyme-like catalytic treatment of tumors.
View Article and Find Full Text PDFJMIR Cancer
September 2025
iCARE Secure Data Environment & Digital Collaboration Space, NIHR Imperial Biomedical Research Centre, London, United Kingdom.
Background: Electronic health records (EHRs) are a cornerstone of modern health care delivery, but their current configuration often fragments information across systems, impeding timely and effective clinical decision-making. In gynecological oncology, where care involves complex, multidisciplinary coordination, these limitations can significantly impact the quality and efficiency of patient management. Few studies have examined how EHR systems support clinical decision-making from the perspective of end users.
View Article and Find Full Text PDF